Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H14ClN3O4S |
Molecular Weight | 367.809 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1ccc(cc1)[C@]([H])(C(=N[C@]2([H])C(=O)N3C(=C(CS[C@]23[H])Cl)C(=O)O)O)N
InChI
InChIKey=QYIYFLOTGYLRGG-GPCCPHFNSA-N
InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1
Molecular Formula | C15H14ClN3O4S |
Molecular Weight | 367.809 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugs.com/pro/cefaclor.htmlCurator's Comment:: description was created based on several sources, including:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/666290
Sources: https://www.drugs.com/pro/cefaclor.html
Curator's Comment:: description was created based on several sources, including:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/666290
Cefaclor is a semisynthetic cephalosporin antibiotic for oral administration. As with other cephalosporins, the bactericidal action of Cefaclor results from inhibition of cell-wall synthesis. Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and Streptococcus pyogenes; Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes; Pharyngitis and Tonsillitis, caused by Streptococcus pyogenes; Urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci; Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes. Adverse effects considered to be related to therapy with cefaclor are: Hypersensitivity reactions, Rarely, reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations, somnolence and diarrhea. Patients receiving Cefaclor may show a false-positive reaction for glucose in the urine with tests that use Benedict's and Fehling's solutions and also with Clinitest® tablets. There have been reports of increased anticoagulant effect when Cefaclor and oral anticoagulants were administered concomitantly.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5748 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16434549 |
1.15 mM [Ki] | ||
Target ID: CHEMBL4605 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16434549 |
4.52 mM [Ki] | ||
Target ID: CHEMBL1743125 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16434549 |
65.0 µM [Ki] | ||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | CEFACLOR Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date1.03109761E12 |
|||
Curative | CEFACLOR Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date1.03109761E12 |
|||
Sources: https://www.drugs.com/pro/cefaclor.html |
Curative | CEFACLOR Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date1.03109761E12 |
||
Sources: https://www.drugs.com/pro/cefaclor.html |
Curative | CEFACLOR Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date1.03109761E12 |
||
Curative | CEFACLOR Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date1.03109761E12 |
|||
Curative | CEFACLOR Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date1.03109761E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2393282/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFACLOR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2393282/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFACLOR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2393282/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFACLOR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: infections Age Group: adult Sources: |
Other AEs: Hypersensitivity... Other AEs: Hypersensitivity (1.5%) Sources: |
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 200 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 200 Sources: |
Other AEs: Creatinine serum increased... Other AEs: Creatinine serum increased (1 patient) Sources: |
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 40 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 40 Sources: |
Other AEs: Aspartate aminotransferase increased, ALT increased... Other AEs: Aspartate aminotransferase increased (1 patient) Sources: ALT increased (1 patient) |
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: |
Other AEs: Eosinophilia, Pruritus genital... Other AEs: Eosinophilia (1 patient) Sources: Pruritus genital (1 patient) Moniliasis (1 patient) Vaginitis (1 patient) |
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 500 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 500 Sources: |
Other AEs: Alkaline phosphatase increased, Blood urea increased... Other AEs: Alkaline phosphatase increased (1 patient) Sources: Blood urea increased (1 patient) |
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 70 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 70 Sources: |
Other AEs: Diarrhea... Other AEs: Diarrhea (1 patient) Sources: |
20 mg/kg/day 3 times / day steady, oral Dose: 20 mg/kg/day, 3 times / day Route: oral Route: steady Dose: 20 mg/kg/day, 3 times / day Sources: |
unhealthy, pediatric Health Status: unhealthy Condition: infections Age Group: pediatric Sources: |
Other AEs: Reaction serum sickness-like... Other AEs: Reaction serum sickness-like (0.5%) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypersensitivity | 1.5% | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: infections Age Group: adult Sources: |
Creatinine serum increased | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 200 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 200 Sources: |
ALT increased | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 40 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 40 Sources: |
Aspartate aminotransferase increased | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 40 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 40 Sources: |
Eosinophilia | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: |
Moniliasis | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: |
Pruritus genital | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: |
Vaginitis | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: |
Alkaline phosphatase increased | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 500 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 500 Sources: |
Blood urea increased | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 500 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 500 Sources: |
Diarrhea | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 70 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 70 Sources: |
Reaction serum sickness-like | 0.5% | 20 mg/kg/day 3 times / day steady, oral Dose: 20 mg/kg/day, 3 times / day Route: oral Route: steady Dose: 20 mg/kg/day, 3 times / day Sources: |
unhealthy, pediatric Health Status: unhealthy Condition: infections Age Group: pediatric Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Encouraging good antimicrobial prescribing practice: a review of antibiotic prescribing policies used in the South East Region of England. | 2001 |
|
Bioequivalence evaluation of two brands of cefaclor 500 mg capsules: quantification of cefaclor using solid phase extraction technique. | 2001 Apr |
|
Recurrent temporal petrositis. | 2001 Apr |
|
Desirable and undesirable immunotropic effects of antibiotics: immunomodulating properties of cefaclor. | 2001 Dec |
|
Enterococcal urinary tract infections: eight years experience at a regional hospital in Trinidad, West Indies. | 2001 Jan |
|
Spectrophotometric determination of selected cephalosporins in drug formulations using flow injection analysis. | 2001 Jul |
|
Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents. | 2001 Jun |
|
Death from multi-resistant shigellosis in Fiji Islands. | 2001 Mar |
|
In vitro and in vivo antibacterial activity and pharmacokinetics of SC-002 and its derivative, SC-004: new oral cephalosporins. | 2001 May-Jun |
|
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001 Nov |
|
High rates of multiple antibiotic resistance in Streptococcus pneumoniae from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission. | 2001 Oct |
|
[Susceptibility to penicillin and 13 antimicrobial agents in erythromycin-resistant viridans group streptococci isolated from blood cultures]. | 2001 Sep |
|
A comparative study of cefaclor vs. amoxicillin/clavulanate in tonsillopharyngitis. | 2001 Sep-Oct |
|
Comparative target site pharmacokinetics of immediate- and modified-release formulations of cefaclor in humans. | 2002 Apr |
|
Comparative efficacy and safety of 5-day cefaclor and 10-day amoxycillin treatment of group A streptococcal pharyngitis in children. | 2002 Jul |
|
Susceptibility change to antibiotics of Staphylococcus aureus strains isolated from skin infections between July 1994 and November 2000. | 2002 Jun |
|
Trends in antimicrobial susceptibility of the Streptococcus milleri group. | 2002 Jun |
|
In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates. | 2002 Mar |
|
[Urinary antimicrobial prophylaxis]. | 2002 May |
|
A case of purpuric drug eruption due to cefaclor. | 2002 Nov |
|
Natural antibiotic susceptibility of Enterobacter amnigenus, Enterobacter cancerogenus, Enterobacter gergoviae and Enterobacter sakazakii strains. | 2002 Sep |
|
Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000. | 2002 Sep |
|
Synthesis and biological activity of tris- and tetrakiscatecholate siderophores based on poly-aza alkanoic acids or alkylbenzoic acids and their conjugates with beta-lactam antibiotics. | 2003 |
|
Natural antimicrobial susceptibilities of strains of 'unusual' Serratia species: S. ficaria, S. fonticola, S. odorifera, S. plymuthica and S. rubidaea. | 2003 Apr |
|
Serotype distribution and antimicrobial resistance patterns in Streptococcus pneumoniae isolates from hospitalized pediatric patients with respiratory infections in Shanghai, China. | 2003 Aug |
|
Modelling and analysing exchangeable binary data with random cluster sizes. | 2003 Aug 15 |
|
Natural antibiotic susceptibility of Proteus spp., with special reference to P. mirabilis and P. penneri strains. | 2003 Feb |
|
Low plasma cefaclor levels in cystectomized bladder cancer patients with various types of urinary diversion. | 2003 Feb |
|
A case of baboon syndrome associated with group a streptococcal infection. | 2003 Jan |
|
Effect of extended-spectrum beta-lactamases on the susceptibility of Haemophilus influenzae to cephalosporins. | 2003 Jan |
|
Natural antibiotic susceptibility of strains of Serratia marcescens and the S. liquefaciens complex: S. liquefaciens sensu stricto, S. proteamaculans and S. grimesii. | 2003 Jul |
|
Antimicrobial resistance in Gram-negative bacteria from Intensive Care Units and Urology Services. A nationwide study in The Netherlands 1995-2000. | 2003 Jun |
|
Reactive metabolites and adverse drug reactions: clinical considerations. | 2003 Jun |
|
A comparative study of cefaclor vs amoxicillin/clavulanate in pediatric pharyngotonsillitis. | 2003 Mar |
|
Rapid and sensitive high-performance liquid chromatographic determination of four cephalosporin antibiotics in pharmaceuticals and body fluids. | 2003 May 5 |
Sample Use Guides
The usual adult dosage is 250 mg every 8 hours. For more severe infections (such as pneumonia) or those caused by less susceptible organisms, doses may be doubled.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/666290
Cefaclor inhibits the gram-negative bacteria. At a level of 12.5 ug/ml, 73% of the E. coli, 90% of the Salmonella, 55% of the Shigella, 77% of the Citrobacter, 91% of the Klebsiella, and 75% of the P. mirabilis isolates were inhibited. However, only 18% of the Enterobacter, 3% of the Serratia, 9% of the Proteus morganii, and 16% of the Providencia strains, and less than 10% of the Proteus vulgaris, Proteus rettgeri, and Bacteroides fragilis isolates, were inhibited. All Pseudomonas strains were as resistant to cefaclor as they were to available cephalosporins.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 04:31:56 UTC 2021
by
admin
on
Sat Jun 26 04:31:56 UTC 2021
|
Record UNII |
3Z6FS3IK0K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175488
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
WHO-ATC |
J01DC04
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
53994-73-3
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | |||
|
4086
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | |||
|
3Z6FS3IK0K
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | |||
|
C76033
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | |||
|
SUB06163MIG
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | |||
|
DB00833
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | |||
|
1450910
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | RxNorm | ||
|
53994-73-3
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | |||
|
M3184
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | Merck Index | ||
|
258-909-5
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | |||
|
51039
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |